Revenues for the first half of 2025 and update on AB Science’s activities
10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
Read more
therapies in diseases
with high medical need
Latest news
AB Science announces a slight delay in the publication of its 2025 half-year financial report
30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest
AB Science announces the successful completion of a 2.55 million euros private placement
04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
24/07/2025 – AB Science today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis has been authorized by the first set of European countries
AB Science announces the successful completion of a EUR 1.925 million private placement
08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors